Denali Therapeutics Inc

NASDAQ:DNLIUnited States

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Contact Information

Headquarters

161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910

Phone

650-866-8548

Fax

302-655-5049

Executives

Independent Chairman of the Board

Vicki Sato

President, Chief Executive Officer, Director

Ryan Watts

Chief Financial Officer, Chief Operating Officer, Company Secretary

Alexander Schuth

Chief Medical Officer

Carole Ho

Director

Steven Krognes